Mounjaro Plus — what the term actually means and what to expect

The decision you're actually making

Choosing to start tirzepatide is rarely just about picking a supplier. The real decision involves three things sitting together: whether the medicine is right for you clinically, who is reviewing that question, and what happens when you have a concern at 10pm on a Sunday. Those three things together are what people mean when they talk about "Mounjaro plus" in any meaningful sense.

The medicine itself is well-characterised. Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) slowing gastric emptying and reducing appetite in ways a single-pathway GLP-1 alone does not replicate. That dual mechanism is why NICE's appraisal of tirzepatide (TA1026) placed it as a recommended option for eligible adults. What varies between providers is everything around the pen: the quality of the initial assessment, how dose increases are handled, and whether someone actually reads your notes before approving a repeat.

At nume (sorry, at our pharmacy) every consultation is read by a GPhC-registered Independent Prescriber. A real clinician reviews your answers, not software. If you're ordering before a bank holiday or you realise on a Thursday that stock needs to reach you by the weekend, the 12 pm Monday-to-Friday cut-off for same-day dispatch is worth building into your plans.

What clinical support around tirzepatide should actually include

A bare prescription is the legal minimum. Structured care is different. A proper Mounjaro treatment plan covers the starting assessment, identity and weight verification, GP notification, and a clinical re-review before every repeat order, not an automated approval based on a box ticked last month.

Dose titration is where this matters most. The 2.5 mg starting dose is not therapeutic in itself; its job is adjustment. Moving from there to Mounjaro 5 mg, and then through higher strengths, should happen at a pace your prescriber judges appropriate based on how you're tolerating the medicine and whether you're seeing a response. Evidence requirements for dose increases and the transfer-patient checks that should accompany switches from another provider are part of that picture, and you can read more about what Mounjaro 2 involves as titration progresses.

Side-effect monitoring is the other pillar. Nausea, loose stools, indigestion and fatigue are common, particularly around dose changes, and usually settle within one to two weeks. Pancreatitis is infrequent but serious: the NHS's patient information on tirzepatide notes that severe or persistent stomach pain radiating to the back warrants urgent medical attention. Knowing who to contact (and getting a real response) is not a nice-to-have.

Cost context: why the cheapest listing answers the wrong question

Prices for tirzepatide in the UK private market vary considerably, and have shifted significantly since Eli Lilly raised its list price in September 2025. Typical private monthly costs now range roughly £149–£375 depending on dose and provider, as widely reported. You can see a fuller breakdown of what drives those numbers on our Mounjaro cost page.

The number to watch is not the headline price, it's what that price includes. Many listings exclude the consultation fee, the prescription charge, delivery, and any ongoing clinical support. A figure that looks lower can become higher once those are added back. For a prescription medicine, the right question is not "which is cheapest?" but "what clinical infrastructure sits behind this?"

nume's single transparent price covers the consultation, prescription, next-working-day tracked delivery and 7-day aftercare. No subscription, no auto-renewal, no surprise fees. We're not positioned as the cheapest option; that is a deliberate choice, not an oversight.

What makes someone eligible, and what happens next

The licensed eligibility criteria for tirzepatide as a weight-management medicine are: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not guarantee approval; the prescriber assesses the full picture, including medical history and any contraindications.

NICE's recommendation under TA1026 applies to NHS provision and carries its own stricter criteria. Private licensed prescribing follows the medicine's SmPC thresholds, and if you want to understand how Mounjaro works within that framework before deciding, our dedicated page sets out the detail clearly. If you're unsure which route is relevant to you, our overview of weight-loss treatment options sets out both clearly.

The practical starting point is a free consultation. If you're approved, treatment is dispatched the same day for orders placed before 12 pm, and arrives the next working day. You can verify our pharmacy on the GPhC register (registration number 9012878) at pharmacyregulation.org, it takes about thirty seconds and is the single most useful check anyone can do before ordering a prescription medicine online.

If you'd like to discuss whether tirzepatide is the right fit, speak to our prescribers, the consultation is free and there's no obligation at the end of it. You can also explore our tirzepatide plus page if you're weighing up whether a more comprehensive support package suits your circumstances.